Cardiovascular Research: Past, Present and Future
DOI:
https://doi.org/10.17140/HROJ-2-112Keywords:
Cardiovascular disease, Heart failure, Cell biology, Drug discovery, Therapeutics, Clinical translationAbstract
Cardiovascular disease remains a leading cause of death and significant burden on
healthcare systems worldwide. While interventional and preventative medicine has considerably
changed the face of clinical practice, at the molecular level, treatment has not altered in
recent decades and is still directed towards alleviating symptoms or mitigating the underlying
cause rather than regenerating damaged heart muscle. This is surprising, given the explosion of
research in this area in the 1970’s, and the fact that research output has continued to increase
exponentially. With the incidence of heart failure on the rise, a trend predicted to continue, it
is imperative that treatment strategies are improved. The development and adoption of molecular
interventions might therefore present the most fruitful avenue in providing the greatest
impact on mortality rates. This commentary aims to reflect on the earliest documented studies
of human cardiovascular physiology, to surgical interventions in the 12th, to the first molecular
studies in the 20th, to current pharmacological treatments. With this knowledge in mind, the
future of molecular approaches in treating heart failure and cardiovascular conditions will be
considered.
References
Hunt SA. American College of Cardiology; American Heart Association Task Force onPractice Guidelines (Writing Commit-tee to update the 2001 Guidelines for the Evaluation and Man-agement of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005; 46(6): e1-e82.
Houser SR, Margulies KB, Murphy AM, et al. Animal models of heart failure: A scientific statement from the American Heart Association. Circ Res. 2012; 111(1): 131-150. doi: 10.1161/ RES.0b013e3182582523
Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ: Heart Failure. 2013; 6(3): 606-619. doi: 10.1161/HHF.0b013e318291329a
Allender S, Peto V, Scarborough P, Laur A, Rayner M. Coro-nary heart disease statistics. British Heart Foundation Statistics Database. 2008.
Derenne JP, Debru A, Grassino AE, Whitelaw WA. The earli-est history of diaphragm physiology. Eur Respir J. 1994; 7(12): 2234-2240. doi: 10.1183/09031936.94.07122234
Apostolakis A, Apostolaki G, Apostolaki M, Chorti M. The reported thoracic injuries in Homer’s Iliad. J Cardiothorac Surg. 2010; 5: 114. doi: 10.1186/1749-8090-5-114
Hajar R. Learning ancient greek medicine from homer. Heart Views. 2002; 3: 8.
Lattimore R. Chicago and London: The University of Chicago Press; 1951.
Singer CJ. A short history of anatomy from the greeks to har-vey. New York, NY: Dover Publications; 1957.
Siddiquey AKS, Husain SMS, Laila SZH. History of anato-my, Editorial. Bangl J Anat. 2009; 7(1): 1-3.
Aird WC. Discovery of the cardiovascular system: from Ga-len to William Harvey. J Thromb Haemost. 2011; 9: 118-129.
Abdel-Halim RE. Experimental medicine 1000 years ago. Urol Ann. 2011; 3(2): 55-61. doi: 10.4103/0974-7796.82168
Key JD, Keys TE, Callahan JA. Historical development of concept of blood circulation. An anniversary memorial essay to William Harvey. Am J Cardiol. 1979; 43: 1026-1032. doi: 10.1016/0002-9149(79)90370-9
Bylebyl JJ. The growth of Harvey’s De motucordis. Bull Hist Med. 1973; 47: 427-470.
Siraisi NG. Medieval and renaissance medicine: continu-ity and diversity. J Hist Med Allied Sci. 1986; 41: 391-394. doi: 10.1093/jhmas/41.4.391
Darwin F. The life and letters of charles darwin. 2000; 2.
Braunwald E. Cardiology: past present and future. J Am Coll Cardiol. 2003; 42(12): 2031-2041. doi: 10.1016/j. jacc.2003.08.025
Einthoven W. The galvanometric registration of the human electrocardiogram, likewise a review of the use of the capillary-electrometer in physiology. Pfluger’s Arch f.d. ges Physiol. 1903; 99: 472-480.
Einthoven W. The Nobel Prize in Physiology or Medicine 1924. Available at: http://www.nobelprize.org/nobel_prizes/ medicine/laureates/1924/ 2014; Accessed May 26, 2015.
White PD. Heart disease. New York, USA. 3rd ed. Macmillan Co; 1944: 1025.
Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease. six-year follow-up experience. The Framingham Study. 3rd ed. Ann Intern Med. 1961; 55: 33-50. doi:10.7326/0003-4819-55-1-33
McCoy AN, Tan SY. Otto Loewi (1873-1961): Dreamer and nobel laureate. Singapore Med J. 2014; 55(1): 3-4. doi: 10.11622/smedj.2014002
Joseph DR. The ratio between the heart-weight and body-weight in various animals. J Exp Med. 1908; 10(4): 521-528.
Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc. Natl. Acad. Sci. 1980; 77: 7380-7384.
Palmiter RD, Brinster RL. Germ-line transformation of mice. Annu. Rev. Genet. 1986; 20: 465-499. doi: 10.1146/an-nurev.ge.20.120186.002341
Swedberg K. History of beta-blockers in congestive heart failure. Heart. 1998; 79 (Suppl 2): S29-S30.
Lauterbur P. MRI - a new way of seeing. Nature. 1973; 190: 191.
Constantinides C, Andrade AA, Pereira AA, Naves ELM, Soares AB. practical applications in biomedical engineering. study of the murine cardiac mechanical function using magnetic resonance imaging. The Current Status, Challenges, and Future Perspectives. Chapter 14. 2013. doi: 10.5772/51364
Neamtu I, Chiriac AP, Diaconu A, Nita LE, Balan V, Nistor MT. Current concepts on cardiovascular stent devices. Mini Rev Med Chem. 2014; 14(6): 505-536. doi: 10.2174/138955751466 6140530093620
Simsekyilmaz S, Liehn EA, Militaru C, Vogt F. Progress in interventional cardiology: challenges for the future. Throm He-most. 2015; 113(3): 464-472. doi: 10.1160/TH14-07-059
Gafoor S, Franke J, Lam S, et al. Devices in heart failure – the new revolution. Circ J. 2015; 79(2): 237-244. doi: 10.1253/ circj.CJ-14-1354
Mancini D, Burkhoff D. Mechanical device–based methods of managing and treating heart failure. Circulation. 2005; 112: 438-448. doi: 10.1161/CIRCULATIONAHA.104.481259
Brunner-La Rocca HP, Vaddadia G, Esler MD. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. J Am Coll Cardiol. 1999; 33(5): 1163-1173. doi: 10.1016/S0735-1097(99)00025-X
Mercola M, Ruiz-Lozano P, Schneider MD. Cardiac muscle regeneration: Lessons from development. Genes Dev. 2011; 25(4): 299-309. doi: 10.1101/gad.2018411
Sanganalmath SK, Bolli R. Cell therapy for heart failure. Circ Res. 2013; 113: 810-834. doi: 10.1161/ CIRCRESAHA.113.300219
Lloyd-Jones DM. Cardiovascular risk prediction. basic con-cepts, current status, and future directions. Circulation. 2010; 121: 1768-1777. doi: 10.1161/CIRCULATIONAHA.109.849166
Würtz P, Havulinna AS, Soininen P, et al. Metabolite profil-ing and cardiovascular event risk: a prospective study of 3 pop-ulation-based cohorts. Circulation. 2015; 131(9): 774-785. doi: 10.1161/CIRCULATIONAHA.114.013116
Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfu-sion injury: A neglected therapeutic target. J Clin Invest. 2013; 123(1): 92-100. doi: 10.1172/JCI62874
van Berlo JH, Maillet M, Molkentin JD. Signalling effec-tors underlying pathologic growth and remodeling of the heart. J Clin Invest. 2013; 123(1): 37-45. doi: 10.1172/JCI62839
Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol. 2012; 165(5): 1235-1245. doi: 10.1111/ j.1476-5381.2011.01700.x
Hausenloy DJ, Kunst G, Boston-Griffiths E, et al. The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: A ran-domised controlled clinical trial. Heart. 2014; 100(7): 544-549. doi: 10.1136/heartjnl-2013-304845
Morel O, Perret T, Delarche N, et al. Pharmacological ap-proaches to reperfusion therapy. Cardiovasc Res. 2012; 94: 246- 252. doi: 10.1093/cvr/cvs114
Pleger ST, Brinks H, Ritterhoff J, et al. Heart failure gene therapy: the path to clinical practice. Circ Res. 2013; 113(6): 792-809. doi: 10.1161/CIRCRESAHA.113.300269
Lipskaia L, Hadri L, Lopez JJ, Hajjar RJ, Bobe R. Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases. Curr Vasc Pharmacol. 2013; 11(4): 465-479. doi: 10.2174/1570 161111311040010#sthash.5R12dHiG.dpuf
Sikkel MB, Hayward C, MacLeod KT, Harding SE, Lyon AR. SERCA2a gene therapy in heart failure: an anti-arrhyth-mic positive inotrope. Br J Pharmacol. 2014; 171: 38-54. doi: 10.1111/bph.12472
Fiedler LR, Maifoshie E, Schneider MD. Mouse models of heart failure: cell signalling and cell survival. Curr Top Dev Biol. 2014; 109: 171-247. doi: 10.1016/B978-0-12-397920- 9.00002-0
Cook SA, Clerk A, Sugden PH. Are transgenic mice the ‘alkahest’ to understanding myocardial hypertrophy and fail-ure? J Mol Cell Cardiol. 2009; 6(2): 118-129. doi: 10.1016/j. yjmcc.2008.11.005
Molkentin JD, Robbins J. With great power comes great re-sponsibility: Using mouse genetics to study cardiac hypertro-phy and failure. J Mol Cell Cardiol. 2009; 46(2): 130-136. doi: 10.1016/j.yjmcc.2008.09.002
Lefer DJ, Bolli R. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limita-tion. J Cardiovasc Pharmacol Ther. 2011; 16: 332-339. doi: 10.1177/1074248411414155
Lecour S, Bøtker HE, Condorelli G, et al. ESC working group cellular biology of the heart: position paper: improving the pre-clinical assessment of novel cardioprotective therapies. Cardio-vasc Res. 2014; 104(3): 399-411. doi: 10.1093/cvr/cvu225
Weiss R, Knight BP, Gold MR, et al. Safety and effi-cacy of a totally subcutaneous implantable-cardioverter de-fibrillator. Circulation. 2013; 128(9): 944-953. doi: 10.1161/ CIRCULATIONAHA.113.003042
Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable car-dioverter-defibrillators: a multicenter case-control study. Heart Rhythm. 2013; 10: 29-36. doi: 10.1016/j.hrthm.2012.09.126
Patel KH, Lambiase PD. The subcutaneous ICD-current evi-dence and challenges. Cardiovasc Diagn Ther. 2014; 4(6): 449- 459. doi: 10.3978/j.issn.2223-3652.2014.12.02
MacLellan WR, Wang Y, Lusis AJ. Systems-based approach-es to cardiovascular disease. Nat Rev Cardiol. 2012; 9(3): 172- 184. doi: 10.1038/nrcardio.2011.208
Fonseca CG, Backhaus M, Bluemke DA, et al. The cardiac atlas project–an imaging database for computational modeling and statistical atlases of the heart. Bioinformatics, 2011; 27(16): 2288-2285. doi: 10.1093/bioinformatics/btr360
Suinesiaputra A, Cowan B, Medrano-Gracia P, Young A. Big heart data: advancing health informatics through data sharing in cardiovascular imaging. IEEE J Biomed Health Inform. 2014. doi: 10.1109/JBHI.2014.2370952
Glatard T, Lartizien C, Gibaud B, et al. A virtual imag-ing platform for multi-modality medical image simulation. IEEE Trans Med Imaging. 2013; 32(1): 110-118. doi: 10.1109/ TMI.2012.2220154
Ohno-Machado L, Bafna V, Boxwala AA, et al. iDASH: integratingdata for analysis, anonymization, and sharing. J Am Med Inform Assoc. 2012; 19(2): 196-201. doi: 10.1136/amiajnl-2011-000538
Goldberger AL, Amaral LA, Glass L, et al. PhysioBank, PhysioToolkit,and PhysioNet: components of a new research resource forcomplex physiologic signals. Circulation. 2000; 101(23): E215-E220. doi: 10.1161/01.CIR.101.23.e215
Winslow RL, Saltz J, Foster I, et al. The CardioVascular Re-search Grid (CVRG) Project. Proc AMIA Summit Transla Bioin-form. 2011; 77-81.
Fan J, Han F, Liu H. Challenges of big data analysis. Natl Sci Rev. 2014; 1(2): 293-314. doi: 10.1093/nsr/nwt032
Mourkioti F, Kustan J, Kraft P, et al. Role of telomere dys-function in cardiac failure in Duchenne muscular dystrophy. Nat Cell Biol. 2013; 15(8): 895-904. doi: 10.1038/ncb2790
D’hooge1 A, Heimdal F, Jamal T, et al. Regional strain and strain rate measurements by cardiac ultrasound: principles, im-plementation and limitations. Eur J Echocardiography. 2000; 1: 154-170. doi: 10.1053/euje.2000.0031
Sherif F, Nagueh MD, Christopher P, et al. Recommenda-tions for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiography. 2009; 10: 165-193.
Stuckey DJ, Carr CA, Martin-Rendon E, et al. Iron particles for noninvasive monitoring of bone marrow stromal cell engraft-ment into, and isolation of viable engrafted donor cells from, the heart. Stem Cells. 2006; 24(8): 1968-1975. doi: 10.1634/ stemcells.2006-0074
Case JA, Bateman TM. Taking the perfect nuclear image: quality control, acquisition, and processing techniques for car-diac SPECT, PET, and hybrid imaging. J Nucl Cardiol. 2013; 20(5): 891-907. doi: 10.1007/s12350-013-9760-9
Saraste A, Knuuti J. Cardiac PET, CT, and MR: what are the advantages of hybrid imaging? Curr Cardiol Rep. 2012; 14(1): 24-31. doi: 10.1007/s11886-011-0231-0
Todiere G, Marzilli M. Role of cardiac imaging in heart fail-ure. Minerva Cardioangiol. 2012; 60(4): 347-362.
Van der Hoeven BL, Schalij MJ, Delgado V. Multimodal-ity imaging in interventional cardiology. Nat Rev Cardiol. 2012; 14(9): 333-346. doi: 10.1038/nrcardio.2012.14
Liang P, Lan F, Lee AS, et al. Drug screening using a li-brary of human induced pluripotent stem cell-derived car-diomyocytes reveals disease-specific patterns of cardiotox-icity. Circulation. 2013; 127(16): 1677-1691. doi: 10.1161/ CIRCULATIONAHA.113.001883
Mordwinkin NM, Burridge PW, Wu JC. A review of human pluripotent stem cell-derived cardiomyocytes for high-through-put drug discovery, cardiotoxicity screening, and publication standards. J Cardiovasc Trans Res. 2013; 6(1): 22-30. doi: 10.1007/s12265-012-9423-2
Sun N, Yazawa M, Liu J, et al. Patient-specific induced pluri-potent stem cells as a model for familial dilated cardiomyopathy. Sci Trans Med. 2012; 4(130): 130ra47.
Charles S, Underwood E. Ashworth. Short history of medi-cine. New York and Oxford: Oxford University Press. 1962; Li-brary of Congress ID: 62-21080.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.